TLSI vs. SGHT, INO, ANGO, UTMD, NPCE, TMCI, GUTS, RCEL, TCMD, and PROF
Should you be buying TriSalus Life Sciences stock or one of its competitors? The main competitors of TriSalus Life Sciences include Sight Sciences (SGHT), Inovio Pharmaceuticals (INO), AngioDynamics (ANGO), Utah Medical Products (UTMD), NeuroPace (NPCE), Treace Medical Concepts (TMCI), Fractyl Health (GUTS), AVITA Medical (RCEL), Tactile Systems Technology (TCMD), and Profound Medical (PROF). These companies are all part of the "surgical & medical instruments" industry.
TriSalus Life Sciences (NASDAQ:TLSI) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, community ranking, media sentiment, valuation and risk.
TriSalus Life Sciences presently has a consensus price target of $16.00, suggesting a potential upside of 62.44%. Sight Sciences has a consensus price target of $4.70, suggesting a potential downside of 11.99%. Given TriSalus Life Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe TriSalus Life Sciences is more favorable than Sight Sciences.
Sight Sciences received 14 more outperform votes than TriSalus Life Sciences when rated by MarketBeat users. However, 100.00% of users gave TriSalus Life Sciences an outperform vote while only 31.91% of users gave Sight Sciences an outperform vote.
In the previous week, TriSalus Life Sciences had 6 more articles in the media than Sight Sciences. MarketBeat recorded 7 mentions for TriSalus Life Sciences and 1 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.75 beat TriSalus Life Sciences' score of 0.23 indicating that Sight Sciences is being referred to more favorably in the news media.
TriSalus Life Sciences has a net margin of 0.00% compared to Sight Sciences' net margin of -67.18%. TriSalus Life Sciences' return on equity of 0.00% beat Sight Sciences' return on equity.
Sight Sciences has higher revenue and earnings than TriSalus Life Sciences.
2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 76.2% of TriSalus Life Sciences shares are owned by company insiders. Comparatively, 27.1% of Sight Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
TriSalus Life Sciences has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.73, suggesting that its share price is 173% more volatile than the S&P 500.
Summary
TriSalus Life Sciences beats Sight Sciences on 8 of the 15 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding TLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
TriSalus Life Sciences Competitors List
Related Companies and Tools